RENB

Renovaro Inc. - Common Stock (RENB)

About Renovaro Inc. - Common Stock (RENB)

Renovaro, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Details

Daily high

$0.38

Daily low

$0.36

Price at open

$0.37

52 Week High

$2.34

52 Week Low

$0.32

Market cap

60.6M

Dividend yield

0.00%

Volume

7,556

Avg. volume

815,956

P/E ratio

-.37

Renovaro Inc. - Common Stock News